Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110746 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Biodel.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01110746 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by Biodel. The registered enrollment target is 20 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01110746, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by Biodel.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
Conditions Studied
Interventions
- DRUG Viaject 7
- DRUG LISPRO
Study Locations (1)
Oregon
- Oregon Health and Science University/Legacy Health System - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110746
The ClinicalTrials.gov registry entry for NCT01110746 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (86% lower). The listed sponsor is Biodel, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Viaject 7 is the first listed.
NCT01110746 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT01110746 about?
NCT01110746 is a clinical study titled "To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy". The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
What is the current status of trial NCT01110746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2010-02. Estimated completion is 2010-06.
What conditions does trial NCT01110746 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT01110746?
The interventions under investigation include: Viaject 7 (DRUG), LISPRO (DRUG).
Who is sponsoring clinical trial NCT01110746?
This trial is sponsored by Biodel, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01110746 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RECRUITING · Phase 3
-
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.